Successful combination of anti-CD33 antibody (gemtuzumab ozogamicin) and minimal conditioning before second allografting in recurrent acute myeloid leukaemia.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Br. J. Haematol.

Title: British journal of haematology

Publisher: Wiley

ISSN: 0007-1048

ISSN (Print): 0007-1048

Publication date (Electronic): Mar 2003

Volume: 120

Issue: 6

Article

Publisher Item ID: 4191_4

DOI: 10.1046/j.1365-2141.2003.04208_4.x

PubMed ID: 12648086

SO-VID: 939bbfc8-9162-4a95-92a9-45703fbe7e6a

History

Data availability:

Comments

Comment on this article

scite_

Cited by 1

Gemtuzumab ozogamicin monotherapy prior to stem cell infusion induces sustained remission in a relapsed acute myeloid leukemia patient after allogeneic stem cell transplantation
Authors: Ritsu Sumiyoshi, Haruko Tashiro, Sumiko Saito …

See all cited by